Let's Drive
the Future
of HS

The INTREPID HS Study is a Phase 3 clinical research study designed to evaluate the safety and efficacy of an investigational drug compared to a placebo (something that looks like the investigational drug but has no effect on the body) in reducing symptoms and improving the quality of life for participants living with HS.

If you qualify, you will be randomly assigned to receive either the investigational drug or placebo for the initial 16 weeks, with both administered as weekly subcutaneous (under the skin) injections. After 16 weeks, all participants, including those initially assigned to receive the placebo, will have the opportunity to receive the investigational drug either weekly or every other week for 36 weeks. All participants will have the opportunity to continue to receive the investigational drug for an additional 156 weeks during the long-term extension. Participating in the study may involve up to 50 visits. Additional visits may be required to receive the investigational drug.